AYTU BIOPHARMA, INC

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

AYTU$1.81+1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Statements of Operations

(in thousands, except share and per share data)

	Three Months Ended
	September 30,
	2025	2024
Net revenue	$13,888	$16,574
Cost of goods sold	4,702	4,589
Gross profit	9,186	11,985
Operating expenses:
Selling and marketing	5,322	5,659
General and administrative	4,924	5,125
Research and development	—	426
Amortization of intangible assets	444	921
Restructuring costs	—	784
Total operating expenses	10,690	12,915
Loss from operations	(1,504)	(930)
Other income, net	201	542
Interest expense	(516)	(994)
Derivative warrant liabilities gain	3,784	2,880
Income from continuing operations before income tax expense	1,965	1,498
Income tax expense	—	(405)
Net income from continuing operations	1,965	1,093
Net income from discontinued operations, net of tax	—	381
Net income	$1,965	$1,474
Basic weighted-average common shares outstanding (note 17)	9,441,073	6,068,019
Diluted weighted-average common shares outstanding (note 17)	19,476,635	9,099,601
Net income (loss) per share (note 17):
Basic - continuing operations	$0.21	$0.18
Diluted - continuing operations	$(0.08)	$(0.20)
Basic - discontinued operations, net of tax	$—	$0.06
Diluted - discontinued operations, net of tax	$—	$0.04
Basic - net income	$0.21	$0.24
Diluted - net loss	$(0.08)	$(0.15)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.